Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma

NCT05303493 is registered in ClinicalTrials.gov with Centre hospitalier de l'Université de Montréal (CHUM) as lead sponsor.

NCT NCT05303493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2022
Completion date
July 15, 2025
Enrollment
45 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, melanoma stage iv, nsclc stage iv, unresectable melanoma